Clinical trials exploring combination therapies have been started to optimize the effects of immunotherapy, particularly in tumor forms with previously limited responses, including lung cancer.582,583 These developments underscore the expanding potential of LSD1 inhibitors in both standalone and combination treatments across a spectrum of cancers. Here, KDM1A is linked to neoplasm.